{"entity":{"id":"nct02697734","kind":"trial","name":"Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease","aka":[],"tldr":"A phase 3 trial of Osilodrostat in Pituitary tumours, run by Novartis Pharmaceuticals, completed.","summary":"Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease is a phase 3 interventional study registered as NCT02697734 by Novartis Pharmaceuticals, with 73 participants recorded, started 2016-10-03 and reaching its primary completion in 2019-06-19. Interventions recorded: osilodrostat, osilodrostat Placebo. Conditions recorded: Cushing's Disease.\n\nLinked to the drug Osilodrostat because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02697734","url":"https://clinicaltrials.gov/study/NCT02697734"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pituitary-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["osilodrostat"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02697734","phase":"3","setting":"A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease","sponsor":"Novartis Pharmaceuticals","started":"2016-10-03","startedType":"actual","yearReported":2021,"enrolled":73,"enrolledBasis":"registry","outcomes":[{"endpoint":"Percentage of Randomized Participants With a Complete Response","primary":true,"unit":"participants","arms":[{"name":"Osilodrostat Group","n":48,"value":37,"note":"Figures from the ClinicalTrials.gov results section (first posted 2021-10-19), not from a publication"},{"name":"Osilodrostat Placebo Group","n":25,"value":2}],"p":"<.0001","source":"https://clinicaltrials.gov/study/NCT02697734?tab=results"}]},"route":"/trials/nct02697734/","neighbours":{"cancer":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"}],"drug":[{"id":"osilodrostat","kind":"drug","name":"Osilodrostat","route":"/drugs/osilodrostat/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}